QLIFE HOLDING AB, Interim Report Q1, January to March 2024
Standing firm and moving forwardFinancial summary – first quarter 2024 · Revenue in the period amounted to kSEK 0 (123). No revenue of Egoo.Health devices and capsules for the device. · EBITDA for the period amounted to kSEK –11,716 (-11,697), and net loss kSEK –8,351(-16,780). · The total cash flow in the first quarter amounted to kSEK 2,714 (-12,110). · Earnings per share before/after dilution for the quarter amounted to SEK -0.01 (-0.73), calculated on weighted average number of shares in the period. Significant events – first quarter of 2024 · Qlife carries out a